Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 473

1.
2.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
3.

Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis.

Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, Hasselblad V, Williams JW Jr.

J Clin Psychiatry. 2014 May;75(5):e424-40. doi: 10.4088/JCP.13r08558. Review.

PMID:
24922495
5.

Barriers to utilizing long-acting injectable antipsychotic medications.

Getzen H, Beasley M, D'Mello DA.

Ann Clin Psychiatry. 2014 Feb;26(1):33-8.

PMID:
24660225
6.

Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012.

Bachmann CJ, Lempp T, Glaeske G, Hoffmann F.

Dtsch Arztebl Int. 2014 Jan 17;111(3):25-34. doi: 10.3238/arztebl.2014.0025.

7.

Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.

Lipscombe LL, Austin PC, Alessi-Severini S, Blackburn DF, Blais L, Bresee L, Filion KB, Kawasumi Y, Kurdyak P, Platt RW, Tamim H, Paterson JM; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.

Schizophr Res. 2014 Apr;154(1-3):54-60. doi: 10.1016/j.schres.2014.01.043. Epub 2014 Feb 24.

8.

[Depressive symptoms diagnosis and treatment of schizophrenia and schizophrenia spectrum disorders in Russian clinical practice].

Gurovich IY, Schmukler AB, Storozhakova YA, Kiryanova EM, Salnikova LI, Gazha AK, Maximova NE, Stepanova ON, Suchkov YA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(11 Pt 2):28-33. Russian.

PMID:
24429962
9.

Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Wheeler AJ, Feetam CL, Harrison J.

Clin Drug Investig. 2014 Mar;34(3):203-11. doi: 10.1007/s40261-013-0166-x.

PMID:
24402882
10.

Walking the fine line: self-reported reasons for substance use in persons with severe mental illness.

Pettersen H, Ruud T, Ravndal E, Landheim A.

Int J Qual Stud Health Well-being. 2013 Dec 20;8:21968. doi: 10.3402/qhw.v8i0.21968.

11.

The effects of antipsychotic switching on diabetes in chronic schizophrenia.

Arnoldy R, Curtis J, Samaras K.

Diabet Med. 2014 Mar;31(3):e16-9. doi: 10.1111/dme.12359.

PMID:
24236701
12.

Treatment considerations for HIV-infected individuals with severe mental illness.

Blank MB, Himelhoch S, Walkup J, Eisenberg MM.

Curr HIV/AIDS Rep. 2013 Dec;10(4):371-9. doi: 10.1007/s11904-013-0179-3. Review.

13.

Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia.

Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S.

Eur Psychiatry. 2014 Jan;29(1):1-10. doi: 10.1016/j.eurpsy.2013.08.001. Epub 2013 Oct 9. Review.

PMID:
24119631
14.

Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.

Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L.

BMC Psychiatry. 2013 Oct 5;13:246. doi: 10.1186/1471-244X-13-246.

15.

Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.

Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, Häkkinen U, Isohanni M, Hakko H.

Schizophr Res. 2013 Oct;150(1):274-80. doi: 10.1016/j.schres.2013.07.043. Epub 2013 Aug 14.

PMID:
23953217
16.

The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.

Hatta K, Takebayashi H, Sudo Y, Katayama S, Kasuya M, Shirai Y, Morikawa F, Nakase R, Nakamura M, Ito S, Kuga H, Nakamura M, Ohnuma T, Usui C, Nakamura H, Hirata T, Sawa Y; JAST study group.

Psychiatry Res. 2013 Dec 15;210(2):396-401. doi: 10.1016/j.psychres.2013.07.005. Epub 2013 Aug 4.

PMID:
23919898
17.

Effect of diagnostic labeling and causal explanations on medical students' views about treatments for psychosis and the need to share information with service users.

Magliano L, Read J, Sagliocchi A, Patalano M, Oliviero N.

Psychiatry Res. 2013 Dec 15;210(2):402-7. doi: 10.1016/j.psychres.2013.07.022. Epub 2013 Jul 31.

PMID:
23916362
18.

Psychiatric intensive care of dementia praecox.

Gaszner G, Bartha A.

Neuropsychopharmacol Hung. 2013 Jun;15(2):118-21.

19.
20.

A mental health initiative to enhance schizophrenia treatment efficacy.

Lalla F, Arshoff L.

Healthc Manage Forum. 2013 Spring;26(1):46-50.

PMID:
23798258
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk